methyl (2R)-piperazine-2-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl (2R)-piperazine-2-carboxylate
• 化学式: C₆H₁₂N₂O₂
• 分子量: 144.17
• InChiKey: ODQZNBWVRPKMKN-RXMQYKEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  50.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• ALICYCLIC HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP1970373A1

  公开（公告）日：2008-09-17

  An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P1 and P2 are CH or N, q and r are 0 to 2, X is -NH-, -O-, -CH2-, etc., Y is -CH2-, -CO-, -SO2-, etc., Z is -CO-, -SO2-, etc., and R3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

  以下是该公式表示的脂环杂环化合物或其药用可接受盐： 其中环A是杂环，环B是碳环，杂环等，P1和P2是CH或N，q和r为0至2，X为-NH-，-O-，-CH2-等，Y为-CH2-，-CO-，-SO2-等，Z为-CO-，-SO2-等，R3为碳环基团，杂环基团，羟基，烷氧基或氨基， 可用作CCR4功能的控制剂，用于预防或治疗支气管哮喘，特应性皮炎等。
• Human Adam-10 Inhibitors
  申请人：Naganathan Sriram

  公开号：US20110003812A1

  公开（公告）日：2011-01-06

  Magnesium salts/complexes of compounds useful for inhibiting the ADAM-IO protein and methods of making and purifying them are provided. Further provided are compositions comprising magnesium salts/complexes of the compounds in combination with a pharmaceutically acceptable carrier. The compounds well as such compositions comprising them are useful for the treatment of cancer, arthritis, diseases related to angiogenesis, such as renal diseases, heart diseases, such as heart failure, atherosclerosis, and stroke, inflammation, ulcer, infertility, scleroderma, endometriosis, mesothelioma, and diabetes. In addition, methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role are provided.

  提供了用于抑制ADAM-IO蛋白质的镁盐/化合物络合物及其制备和纯化方法。此外，还提供了包含镁盐/化合物络合物的组合物，与药用载体结合。这些化合物以及包含它们的组合物对于治疗癌症、关节炎、与血管生成有关的疾病，如肾脏疾病、心脏疾病，如心力衰竭、动脉粥样硬化和中风、炎症、溃疡、不孕症、硬皮病、子宫内膜异位症、间皮瘤和糖尿病方面具有用处。此外，还提供了治疗癌症、关节炎和与ADAM-10发挥关键作用的血管生成相关疾病的方法。
• Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors
  申请人：Wood Alastair J.J.

  公开号：US20110082114A1

  公开（公告）日：2011-04-07

  The present invention provides methods of treating aneurysmal dilatation, blood vessel wall weakness, and specifically abdominal aortic aneurysm and thoracic aneurysm by inhibiting MMPs and ADAM-10. Such compounds are useful in the in vitro study of the role of MMPs and ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more MMPs or ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm. The invention also comprises methods of treating aneurysmal dilatation or blood vessel wall weakness, for example abdominal aortic aneurysm and thoracic aneurysm utilizing the compounds of the invention in conjunction with inhibitors of angiotensin II, including angiotensin II receptor blockers and angiotensin converting enzyme inhibitors, and cyclophilin inhibitors.

  本发明提供了通过抑制MMPs和ADAM-10来治疗动脉瘤扩张、血管壁薄弱，特别是腹主动脉瘤和胸主动脉瘤的方法。这些化合物在体外研究中对MMPs和ADAM-10（及其抑制作用）在生物过程中的作用具有用处。本发明还包括包含根据本发明的一种或多种MMPs或ADAM-10抑制剂与药学上可接受的载体组合的药物组合物。这些组合物对于治疗动脉瘤扩张或血管壁薄弱，例如腹主动脉瘤和胸主动脉瘤，具有用处。本发明还包括利用本发明的化合物与血管紧张素II的抑制剂（包括血管紧张素II受体拮抗剂和血管紧张素转换酶抑制剂）以及环肽酶抑制剂一起治疗动脉瘤扩张或血管壁薄弱的方法。
• [EN] DIHYDROPTERIDINONE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF<br/>[FR] DÉRIVÉS DE DIHYDROPTÉRIDINONE, PROCÉDÉ DE PRÉPARATION ET UTILISATION PHARMACEUTIQUE ASSOCIÉS
  申请人：JIANGSU HENGRUI MEDICINE CO

  公开号：WO2011113293A1

  公开（公告）日：2011-09-22

  本发明涉及二氢喋啶酮类衍生物、其制备方法及其在医药上的应用。具体而言，本发明涉及一种通式（Ⅰ）所示的新的二氢喋啶酮类衍生物、其制备方法及含有该衍生物的药物组合物以及其作为治疗剂特别是作为Plk激酶抑制剂的用途，其中通式（Ⅰ）的各取代基与说明书中的定义相同。
• US7629341B2
  申请人：——

  公开号：US7629341B2

  公开（公告）日：2009-12-08